Phentermine vs GLP-1 Medications: Which Is Right for You?

Phentermine has been the most prescribed anti-obesity medication in the United States for decades. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — are newer but have rapidly become the dominant class in obesity pharmacotherapy. Patients and clinicians now face a practical question: which approach delivers better results, and for whom?

This comparison breaks down the clinical evidence on efficacy, safety, cost, and real-world use to help you make an informed decision.

How Each Drug Class Works

Phentermine: Appetite Suppression via the Central Nervous System

Phentermine is a sympathomimetic amine approved by the FDA in 1959. It works by stimulating the release of norepinephrine and, to a lesser degree, dopamine in the hypothalamus — reducing hunger signals and increasing energy expenditure. Because of its stimulant properties, phentermine is classified as a Schedule IV controlled substance and approved only for short-term use (typically up to 12 weeks), though real-world prescribing patterns commonly extend beyond that window.

Evidence: "Over 60 years of clinical use supports phentermine's safety in appropriate patients, with evidence of minimal psychological dependence risk; panelists suggest its future role may be as adjunctive combination therapy as GLP-1 agents become standard of care." — Bays HE, et al. Obesity Pillars. 2022. DOI: 10.1016/j.obpill.2022.100024

Phentermine is also available as a fixed-dose combination with topiramate (brand name Qsymia), which adds a second mechanism — anticonvulsant activity that further reduces appetite and increases satiety.

GLP-1 Receptor Agonists: Hormonal Regulation of Appetite and Metabolism

GLP-1 (glucagon-like peptide-1) agonists mimic a natural gut hormone released after meals. They act on receptors in the brain, pancreas, stomach, and gut to:

• Slow gastric emptying (food stays in the stomach longer)
• Increase insulin secretion in response to meals
• Suppress glucagon release
• Reduce appetite through hypothalamic signaling

Unlike phentermine, GLP-1 medications are not stimulants and carry no dependency risk. They are approved for long-term use. Current options approved for chronic weight management include semaglutide 2.4 mg (Wegovy), liraglutide 3.0 mg (Saxenda), and tirzepatide 15 mg (Zepbound).

Efficacy: What the Evidence Shows

Weight Loss Outcomes

A landmark 2024 Lancet network meta-analysis of 132 randomized controlled trials involving 48,209 participants provides the most comprehensive comparison across drug classes:

Evidence: "Phentermine-topiramate and GLP-1 receptor agonists were the most effective drug classes for weight reduction; semaglutide achieved approximately -11.4% bodyweight versus lifestyle alone." — Shi Q, et al. The Lancet. 2024. DOI: 10.1016/S0140-6736(24)00351-9

A second large network meta-analysis of 168 RCTs (97,938 patients) confirmed these rankings:

Evidence: "Semaglutide and phentermine/topiramate produced greater body weight loss and waist circumference reduction at 12 months than all other drugs studied — approximately -9 kg and -8 kg versus placebo, respectively." — Iannone A, et al. Diabetes, Obesity and Metabolism. 2023. DOI: 10.1111/dom.15138

The numbers, summarized:

Medication	Average Weight Loss vs. Placebo	Duration
Semaglutide 2.4 mg	~15% body weight	68 weeks
Tirzepatide 15 mg	~20.9% body weight	72 weeks
Liraglutide 3.0 mg	~5–8% body weight	56 weeks
Phentermine alone	~3–8% body weight	12–24 weeks
Phentermine/topiramate ER	~8–11% body weight	56 weeks

A systematic review directly comparing semaglutide, liraglutide, orlistat, and phentermine found all four agents produced clinically meaningful weight loss, but the GLP-1 agents — particularly semaglutide — showed superior outcomes:

Evidence: "All four agents produced clinically meaningful weight loss, but differed in safety profiles — GLP-1 agonists (semaglutide, liraglutide) caused gastrointestinal side effects, while phentermine carries potential for dependency." — Patel JP, et al. Cureus. 2025. DOI: 10.7759/cureus.80321

Combination Therapy: Can You Use Both?

A randomized pilot trial tested adding phentermine 15 mg to ongoing liraglutide 3.0 mg treatment:

Evidence: "Adding phentermine 15 mg to ongoing liraglutide 3.0 mg therapy did not produce statistically significant additional weight loss (-1.6% vs -0.1%, p=0.073) in patients who had already lost ~12.6% on liraglutide alone, though the combination was well tolerated." — Tronieri JS, et al. Metabolism. 2019. DOI: 10.1016/j.metabol.2019.03.005

While the combination was safe, the added benefit was modest in patients already responding well to liraglutide. Research in this area is ongoing.

Safety and Side Effects

Phentermine

Common side effects include:

• Elevated heart rate and blood pressure
• Insomnia, anxiety, irritability
• Dry mouth, constipation
• Headache, dizziness

Contraindications: Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or history of drug abuse. It should not be used during pregnancy.

The long-term cardiovascular data gap is a meaningful concern:

Evidence: "Despite being the most frequently prescribed anti-obesity medication in the US, phentermine lacks long-term cardiovascular outcomes data. Large observational studies have not found increased cardiovascular risk." — Lewis KH, et al. Current Obesity Reports. 2024. DOI: 10.1007/s13679-023-00546-9

Phentermine/Topiramate (Qsymia)

The combination product adds topiramate-related adverse effects:

Evidence: "Phentermine/topiramate produced an average of -7.73 kg versus placebo, with the primary safety concern being nervous system adverse events (dysgeusia, paresthesia, dry mouth)." — Lei XG, et al. Obesity (Silver Spring). 2021. DOI: 10.1002/oby.23152

Topiramate is also a known teratogen — Qsymia carries an FDA boxed warning and requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program.

GLP-1 Receptor Agonists

GLP-1 medications carry a different side effect profile:

• Gastrointestinal effects: Nausea, vomiting, diarrhea, constipation (most common, often transient)
• Injection site reactions (for subcutaneous formulations)
• Rare but serious: Pancreatitis, gallbladder disease, rare thyroid C-cell tumors (animal studies only for semaglutide; contraindicated in personal/family history of MTC or MEN2)

GLP-1 agonists do not elevate blood pressure or heart rate. Semaglutide has cardiovascular benefit data: the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in adults with obesity and established CVD.

Cost and Accessibility

Phentermine remains one of the most affordable weight loss medications available — generic phentermine costs as little as $10–30/month without insurance. This accessibility has sustained its widespread use for 60+ years.

GLP-1 medications are substantially more expensive. Without insurance:

• Wegovy (semaglutide 2.4 mg): ~$1,300–1,500/month
• Zepbound (tirzepatide): ~$1,000–1,300/month
• Saxenda (liraglutide): ~$1,200–1,500/month

Insurance coverage varies widely. Many commercial plans cover GLP-1s for obesity; Medicare Part D covers them only for cardiovascular risk reduction (SELECT trial indication) as of 2024. Coverage gaps remain a significant barrier.

Who Should Consider Phentermine

Phentermine may be appropriate when:

• Cost is a primary concern
• Short-term intervention is needed (kickstarting weight loss before other treatment)
• GLP-1 medications are contraindicated or unavailable
• The patient has no contraindications (normal blood pressure, no cardiac history, no substance use disorder)
• Used as a bridge while awaiting GLP-1 insurance approval

Phentermine is less appropriate for:

• Long-term obesity management
• Patients with hypertension, anxiety, or cardiovascular disease
• Those who need sustained appetite suppression beyond 12 weeks

Who Should Consider GLP-1 Medications

GLP-1 receptor agonists are the preferred first-line pharmacotherapy when:

• Greater weight loss is needed (>10% body weight)
• The patient has type 2 diabetes or prediabetes
• Cardiovascular disease or risk factors are present (semaglutide has proven CV benefit)
• Long-term, maintained treatment is the goal
• Phentermine's stimulant effects are contraindicated

The greater absolute weight loss with GLP-1 agents — particularly semaglutide and tirzepatide — makes them the stronger option for patients with significant obesity (BMI ≥35 with comorbidities or BMI ≥40).

Key Takeaways

• Efficacy: GLP-1 medications (especially semaglutide and tirzepatide) produce greater weight loss than phentermine alone. Phentermine/topiramate narrows the gap but still falls short of GLP-1 outcomes.
• Safety: Phentermine raises heart rate and blood pressure and lacks long-term cardiovascular outcomes data. GLP-1 medications have proven cardiovascular benefit and no stimulant effects.
• Cost: Phentermine is dramatically cheaper ($10–30/month vs. $1,000–1,500/month for GLP-1s).
• Duration: Phentermine is approved for short-term use; GLP-1s are designed for ongoing treatment.
• Best candidate for phentermine: Cost-constrained patient, no cardiac risk factors, short-term goal.
• Best candidate for GLP-1: Greater weight loss needed, long-term management, cardiovascular risk present.

For many patients, the decision comes down to access and insurance coverage. Where both are viable, evidence strongly favors GLP-1 receptor agonists for sustained, clinically meaningful weight loss.

For more on specific GLP-1 options, see Ozempic vs Wegovy: What's the Difference? and Starting GLP-1: What to Expect in Your First 3 Months.

---

References

1. Patel JP, Hardaswani D, Patel J, et al. Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. Cureus. 2025;17(3):e80321. DOI: 10.7759/cureus.80321

2. Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. The Lancet. 2024;403(10434):e21–e31. DOI: 10.1016/S0140-6736(24)00351-9

3. Iannone A, Natale P, Palmer SC, et al. Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2023;25(9):2535–2544. DOI: 10.1111/dom.15138

4. Tronieri JS, Wadden TA, Walsh OA, et al. Effects of Liraglutide Plus Phentermine in Adults with Obesity Following 1 Year of Treatment by Liraglutide Alone: A Randomized Placebo-Controlled Pilot Trial. Metabolism. 2019;96:83–91. DOI: 10.1016/j.metabol.2019.03.005

5. Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2021;29(6):985–994. DOI: 10.1002/oby.23152

6. Lewis KH, Gudzune KA, Ard JD. Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment? Current Obesity Reports. 2024;13(1):132–140. DOI: 10.1007/s13679-023-00546-9

7. Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: Phentermine – Past, present, and future. Obesity Pillars. 2022;3:100024. DOI: 10.1016/j.obpill.2022.100024

---

Last updated: 2026-03-20 Medical review: Dr. James Chen, MD, PhD, FACE